VistaGen Therapeutics Inc (VTGN)

[Fress]

VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year.

Cash runway into 2023

Multiple offers on the table for VTGN companies want a blockbuster next generation low side effects fast acting depression and anxiety drugs 16 drugs in the pipeline massive.

VTGN has all the boxes checked off. 115 million plus cash in the bank.

Deep pipeline 16 drugs next generation depression and anxiety meds.

VTGN fast acting 15 min & low side effects.

First generation depression meds have a 30% success rate at best very high side effects & takes months to start to take effect.


VTGN Phase 3 ready Fast tracked. Social Anxiety Disorder.

Multiple phase 2's including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)



VTGN multi billion dollar depression/anxiety pipeline Be Patient & add at these levels. If Mindmed is valued at 1 Billion market capitalization roughly 30 million in cash nearing phase 2B is MMEDF furthest drug out in trials.


VTGN 115 million in cash market cap 360 million Phase 3 Ready Anxiety low side effects fast acting and a phase 2 Covid fast tracked indication for depression starting early 2021 both. fast tracked. This stock probably be 20.00+ 2021-2022 Buy and hold. multi Billion dollar market cap in the making.

next generation depression and anxiety drugs is a smart place to be invested for massive ROI.

World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/


Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU


https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey

VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash

Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.


93% increase in people participating in anxiety screenings, according to Mental Health America.



$VTGN